Defence Therapeutics Inc.

OTC: DTCFF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Vancouver, QCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 29DQ —GM —SS 53

v0.1 · 35/100 weight · pillars only

↑ workforce scale, Altman-Z · ↓ return on assets, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.9M

Employees

1,300

Market cap

$17.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$2.9M-4.0M CAD2025

Operating income-$2.1M-3.0M CAD2025

Total assets$1.2M1.7M CAD2025

Liabilities$2.1M2.9M CAD2025

Equity-$733.0k-1.0M CAD2025

Revenue trend

FY2019 – FY2025 · USD

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Defence Therapeutics Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Oncotelic Therapeutics, Inc.46D Perimeter Medical Imaging AI, Inc.39D Aytu BioPharma, Inc.53D ProMIS Neurosciences, Inc.——

Key facts

CEOSébastien Plouffe

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersVancouver, QC

ExchangeOTC: DTCFF

Employees1,300

IPO date2021-05-18

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.